=== PAGE 5 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its original layout and structure:

Ms. Ann Robards
Eli Lilly and Company
BLA 125469/MA 1035

Page 5

The concerns discussed in this letter do not necessarily constitute an exhaustive list of
potential violations. It is your responsibility to ensure compliance with each applicable
requirement of the FD&C Act and FDA implementing regulations.

Please direct your response to the undersigned at the **Food and Drug Administration,
Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-
B Ammendale Road, Beltsville, Maryland 20705-1266**. A courtesy copy can be sent by
facsimile to (301) 847-8444. To ensure timely delivery of your submissions, please use the
full address above and include a prominent directional notation (e.g., a sticker) to indicate that
the submission is intended for OPDP. Please refer to MA 1035 in addition to the BLA
number in all future correspondence relating to this particular matter. All correspondence
should include a subject line that clearly identifies the submission as a Response to Untitled
Letter.

Sincerely,

{See appended electronic signature page}

Samantha Bryant, PharmD, BCPS
Regulatory Review Officer
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

{See appended electronic signature page}

Melinda Wilson, PharmD, MPH, BCPS, RAC
Team Leader
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

Reference ID: 4922588
